# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to...
https://www.ft.com/content/5272ebe0-146c-484c-8ae3-6fb6edc71fbb
Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) with a Hold.
https://www.wsj.com/articles/bausch-plan-to-spin-off-eye-care-business-stuck-in-creditor-standoff-00e49ff8
RBC Capital analyst Douglas Miehm reiterates Bausch & Lomb (NYSE:BLCO) with a Outperform and maintains $20 price target.
HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb (NYSE:BLCO) with a Buy and lowers the price target from ...
Deutsche Bank analyst Pito Chickering maintains Bausch & Lomb (NYSE:BLCO) with a Hold and raises the price target from $...